Patrick McManamny regularly counsels clients in relation to filing and management of international patent portfolios, freedom-to-operate issues, patentability and due diligence. He has substantial experience in protecting and conducting due diligence in relation to biological therapeutics such as antibodies, proteins, peptides and stem cells and processes for their manufacture. Patrick also has experience in diagnostics and drug screening methods.
His clients include large multi-national clients, start-up companies and research institutes. Patrick has also served a brief period as in-house counsel, which provided valuable insight into the responsibilities of this role.
He has experience in developing and managing complex patent portfolios, including developing strategies to coincide with regulatory filings. He also regularly leads teams in conducting large due diligence and freedom-to-operate analysis projects.
His approach to resolving legal issues revolves around reaching the solution which best meets his client's business needs. Patrick’s technical expertise arise from his PhD primarily focused molecular biology and physiology.
Patrick is a registered patent attorney in Australia and New Zealand.
"The pharmaceutical patent landscape is complex and constantly evolving. At FB Rice, we work with our clients to ensure they are aware of these changes and their effect on their business and goals, whether this is obtaining patent rights or being aware of, or avoiding, third party rights."